SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

aleniglipron

GPCR·Structure Therapeutics Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Phase 3 topline data expected in 2H 2028. If successful, an FDA submission and potential approval would follow, likely in 2029-2030 at the earliest.
Why 4/10
The next hard, dated binary catalyst (Phase 3 topline data from ACCOMPLISH-1/ACCOMPLISH-2) is expected in 2H 2028, more than 12 months away. Near-term events (ObesityWeek presentation on Nov 15, 2026 and supplementary Q4 readouts) are data presentations of existing or exploratory analyses, not pivotal binary readouts. Per the rubric, a mid-stage drug whose next catalyst is >12 months out scores 3-5; 4 reflects that aleniglipron is the company's lead asset but lacks a near-term binary catalyst.
Actionable Insight NEUTRAL

Watch the ObesityWeek 2026 presentation on November 15 for any incremental efficacy or tolerability detail on aleniglipron, and the three supplementary data readouts due in Q4 2026 (body composition, sleep apnea, and other analyses). The next major binary catalyst is the Phase 3 ACCOMPLISH topline data in 2H 2028, leaving a long stretch where competitive developments from Lilly's Foundayo and Novo Nordisk's oral programs will likely drive sentiment more than company-specific news.

Price Chart

Loading chart...

Executive Summary

Aleniglipron is Structure Therapeutics' lead asset: an oral small-molecule GLP-1 receptor agonist for obesity. Phase 2 data showed up to 16.2% weight loss at 72 weeks, among the highest reported for an oral GLP-1, with a tolerable side-effect profile. Phase 3 ACCOMPLISH trials are enrolling with topline data expected in 2H 2028. The company holds $1.24 billion in cash, funding operations through 2028. However, the stock has fallen from a $94.90 52-week high to ~$21 as Eli Lilly's competing oral GLP-1 (Foundayo/orforglipron) has already won FDA approval for obesity and is expanding into sleep apnea and diabetes. The GLP-1 market is intensely competitive, with Novo Nordisk and others also developing oral alternatives. Analyst consensus is Strong Buy with a mean target of ~$104, implying ~380% upside from the current price, but the next pivotal binary catalyst is roughly two years away.

How It Works

Aleniglipron is a once-daily oral pill that mimics a natural hormone called GLP-1, which tells the body to feel fuller longer, release more insulin, and slow digestion. Unlike injectable obesity drugs such as Wegovy and Ozempic, aleniglipron is a small molecule (not a peptide), so it can be taken as a simple pill with or without food rather than requiring an injection.

Trial Status

Aleniglipron completed a successful Phase 2 program (ACCESS and ACCESS II trials) showing up to 16.2% weight loss at 72 weeks in an open-label extension. The Phase 2b ACCESS trial (36 weeks) showed 12.1% weight loss at the highest dose, published in Nature Medicine in June 2026. The Phase 2 ACCESS II trial (44 weeks) showed placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg with no evidence of a weight-loss plateau. Two Phase 3 registrational trials, ACCOMPLISH-1 and ACCOMPLISH-2, are now enrolling patients, with topline data expected in the second half of 2028.

The Two-Sided Case

▲ Bull Case4
Phase 2 data showed up to 16.2% weight loss at 72 weeks, among the highest efficacy reported for any oral GLP-1, with no evidence of a weight-loss plateau and low adverse-event discontinuation rates.
The company has a strong cash position of $1.24 billion, funding operations and the Phase 3 program through end of 2028 without near-term dilution risk.
Analyst consensus is Strong Buy (21 analysts: 13 Buy, 8 Strong Buy) with a mean price target of $104.31, representing roughly 380% upside from the current ~$21 stock price.
Major institutional holders include FMR LLC ($419M), Wellington Management ($396M), and Avoro Capital ($352M) as of Q2 2026, signaling long-term institutional conviction.
▼ Bear Case5
Eli Lilly's oral GLP-1 Foundayo (orforglipron) was already FDA-approved for obesity in January 2026 and is now pursuing additional approvals for sleep apnea and type 2 diabetes, creating a multi-year commercial head start.
The stock has collapsed roughly 78% from its 52-week high of $94.90 to ~$21, reflecting market skepticism about aleniglipron's ability to compete in the increasingly crowded GLP-1 market.
Phase 3 topline data is not expected until 2H 2028, leaving a long period without a binary catalyst and exposing the stock to competitive news flow from Lilly and Novo.
Insiders (CMO and CSO) sold shares in August-September 2026 via 10b5-1 plans at prices between $36-$55, well above the current ~$21 level.
Several large institutional holders trimmed or exited positions in Q2 2026, including Price T Rowe (trimmed 57.7%), Balyasny (exit), and Pentwater Capital (exit).

Upcoming Catalysts

  • ObesityWeek 2026 presentation on November 15, 2026: Dose-Ranging Effects of Aleniglipron (the ACCESS Trials)
  • Three supplementary aleniglipron data readouts due in Q4 2026 (body composition, sleep apnea, and other analyses per company guidance)
  • Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 topline data expected in 2H 2028

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Structure Therapeutics Inc. PRESS-RELEASE GPCR ·Originating report

Sources · 10

Hover a chip for the title
1 rttnews.com2 markets.businessinsider.com3 sciencedaily.com4 fiercebiotech.com5 seekingalpha.com6 seekingalpha.com7 markets.businessinsider.com8 biospace.com9 nasdaq.com10 sec.gov